European Commission approves Novartis’ Itvisma to treat SMA
With this decision, Itvisma becomes the only gene replacement therapy which is currently approved for this wider patient population within the EU. Itvisma works by providing a functional
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.